UCB, the Belgian biopharma, reported positive results from a China Phase III trial of its transdermal patch product, NEUPRO®, a treatment for early stage Parkinson’s disease. NEUPRO (rotigotine) is a dopamine agonist. In a double blind test, the product improved patients’ ability to do routine daily tasks and their motor function scores compared to placebo. UCB expects to file for China approval this year; NEUPRO is already sold in the US, Europe and Japan.
Help employers find you! Check out all the jobs and post your resume.
